Clinical Trial Update: Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical trial assessing the efficacy and safety of Everolimus (RAD001) in patients with advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Gastric Cancer | Phase 2 | Status: COMPLETED